Literature DB >> 20497033

Direct generation of induced pluripotent stem cells from human nonmobilized blood.

Atsushi Kunisato1, Mariko Wakatsuki, Haruna Shinba, Toshio Ota, Isao Ishida, Kenji Nagao.   

Abstract

The use of induced pluripotent stem cells (iPSCs) is an exciting frontier in the study and treatment of human diseases through the generation of specific cell types. Here we show the derivation of iPSCs from human nonmobilized peripheral blood (PB) and bone marrow (BM) mononuclear cells (MNCs) by retroviral transduction of OCT3/4, SOX2, KLF4, and c-MYC. The PB- and BM-derived iPSCs were quite similar to human embryonic stem cells with regard to morphology, expression of surface antigens and pluripotency-associated transcription factors, global gene expression profiles, and differentiation potential in vitro and in vivo. Infected PB and BM MNCs gave rise to iPSCs in the presence of several cytokines, although transduction efficiencies were not high. We found that 5 × 10(5) PB MNCs, which corresponds to less than 1 mL of PB, was enough for the generation of several iPSC colonies. Generation of iPSCs from MNCs of nonmobilized PB, with its relative efficiency and ease of harvesting, could enable the therapeutic use of patient-specific pluripotent stem cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20497033     DOI: 10.1089/scd.2010.0063

Source DB:  PubMed          Journal:  Stem Cells Dev        ISSN: 1547-3287            Impact factor:   3.272


  30 in total

Review 1.  Human induced pluripotent stem cells--from mechanisms to clinical applications.

Authors:  Katharina Drews; Justyna Jozefczuk; Alessandro Prigione; James Adjaye
Journal:  J Mol Med (Berl)       Date:  2012-05-30       Impact factor: 4.599

2.  iPSCs: Unstable origins?

Authors:  Sayandip Mukherjee; Adrian J Thrasher
Journal:  Mol Ther       Date:  2011-07       Impact factor: 11.454

Review 3.  Methods of induced pluripotent stem cells for clinical application.

Authors:  Tomohisa Seki; Keiichi Fukuda
Journal:  World J Stem Cells       Date:  2015-01-26       Impact factor: 5.326

Review 4.  Promise and challenges of human iPSC-based hematologic disease modeling and treatment.

Authors:  Zhaohui Ye; Bin-Kuan Chou; Linzhao Cheng
Journal:  Int J Hematol       Date:  2012-05-23       Impact factor: 2.490

Review 5.  Delivery of nucleic acid therapeutics by genetically engineered hematopoietic stem cells.

Authors:  Christopher B Doering; David Archer; H Trent Spencer
Journal:  Adv Drug Deliv Rev       Date:  2010-09-30       Impact factor: 15.470

6.  Comparing the reprogramming efficiency of mouse embryonic fibroblasts, mouse bone marrow mesenchymal stem cells and bone marrow mononuclear cells to iPSCs.

Authors:  Lei Wang; Mingyan Zhu; Qingsong Guo; Xiangjun Fan; Yuhua Lu; Shajun Zhu; Yao Wang; Yan Huang; Zhiwei Wang
Journal:  In Vitro Cell Dev Biol Anim       Date:  2012-03-29       Impact factor: 2.416

Review 7.  Harnessing the potential of induced pluripotent stem cells for regenerative medicine.

Authors:  Sean M Wu; Konrad Hochedlinger
Journal:  Nat Cell Biol       Date:  2011-05       Impact factor: 28.824

8.  Induced pluripotent stem cell reprogramming by integration-free Sendai virus vectors from peripheral blood of patients with craniometaphyseal dysplasia.

Authors:  I-Ping Chen; Keiichi Fukuda; Noemi Fusaki; Akihiro Iida; Mamoru Hasegawa; Alexander Lichtler; Ernst J Reichenberger
Journal:  Cell Reprogram       Date:  2013-11-12       Impact factor: 1.987

Review 9.  New frontier in regenerative medicine: site-specific gene correction in patient-specific induced pluripotent stem cells.

Authors:  Zita Garate; Brian R Davis; Oscar Quintana-Bustamante; Jose C Segovia
Journal:  Hum Gene Ther       Date:  2013-06       Impact factor: 5.695

10.  Generation of integration-free human induced pluripotent stem cells from postnatal blood mononuclear cells by plasmid vector expression.

Authors:  Sarah N Dowey; Xiaosong Huang; Bin-Kuan Chou; Zhaohui Ye; Linzhao Cheng
Journal:  Nat Protoc       Date:  2012-10-18       Impact factor: 13.491

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.